Medpace Holdings Inc vs PayPal Holdings, Inc. — how do they compare? Medpace Holdings Inc trades at $530.58 (market cap $15.08B), while PayPal Holdings, Inc. trades at $55.94 (market cap $50.12B). The key difference: PayPal Holdings, Inc. is far larger — about 3.3× Medpace Holdings Inc's market cap, and PayPal Holdings, Inc. pays a 0.99% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals.
| MEDP | PYPL | |
|---|---|---|
Market Cap | $15.08B | $50.12B |
Sector | Technology | Financials |
52-Week High | $620.59 | $78.22 |
52-Week Low | $308.88 | $39.08 |
Enterprise Value | $14.55B | $50.19B |
Dividend Yield | — | 0.99% |
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $527.93, down 1.82% today, with a bullish technical outlook supported by moving averages. The company demonstrates strong profitability with 17.19% net margins and 77.25% ROE, though valuation ratios appear elevated with a P/E of 33.83. Recent earnings have consistently beaten expectations, and cash flow is projected to improve significantly in 2026. However, the stock faces headwinds from ongoing class action lawsuits and mixed analyst sentiment with 73.69% hold ratings.
MEDP presents a mixed investment case with strong fundamental performance offset by legal overhangs and premium valuation. The company's consistent earnings beats and projected cash flow improvement support upside potential, but investors should weigh the legal risks and cautious analyst stance against the robust operational metrics.
PayPal (PYPL) trades at $56.78, up 0.38% with strong technical momentum as the stock approaches resistance near $57-$59 following a $53 billion takeover bid from Stripe and Advent International. The company shows solid fundamentals with 2025 revenue of $33.17B, net income of $5.23B (15% margin), and attractive valuation metrics including a P/E of 10.6 and P/S of 1.6. Recent earnings beat expectations in Q1 2026 with EPS of $1.34 versus $1.27 expected.
The acquisition offer at $60.50 per share provides near-term upside potential, though the board considers it undervalued. Key risks include regulatory hurdles for the deal and competitive pressures in digital payments. Analyst sentiment is mixed with 36% buy ratings but a consensus price target of $50.80 below current levels, suggesting cautious optimism amid takeover speculation.
Trailing returns across standard periods
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →PayPal Holdings, Inc. operates as a technology platform company that enables digital and mobile payments on behalf of consumers and merchants. The Company offers online payment solutions. PayPal Holdings serves customers worldwide.
Read more on PYPL →